In our next episode on tariffs, President Donald Trump has declared his intention to impose a 25% tariff—or potentially higher—on imported vehicles, pharmaceuticals, and semiconductors. As usual, the plan is long on rhetoric, and short on specifics.
If enacted at scale, this initiative would strike more than $500 billion worth of goods, encompassing supply chains that link the US with close allies such as Canada, Mexico, the European Union, Japan, and Taiwan.
When asked about auto tariffs in a press conference, Trump answered that he “probably will tell you that on April 2nd, but it will be in the neighborhood of 25%.” Soon after, he mentioned the same 25% figure in relation to semiconductors and pharmaceuticals, adding that it could be “substantially higher.”
Sponsored · Selkirk Copper Mines
“We want to give them time to come in because, as you know, when they come into the United States and they have their plant or factory here, there is no tariff,” he added.
At the heart of the controversy is Trump’s longstanding claim that Canada and Mexico, among others, have eroded the US automobile industry by siphoning production away from states like Michigan and Ohio.
Auto executives and economists, however, counter that vehicles are no longer purely “Canadian” or “American” products. A 25% tariff, experts warn, would slow sales and production on both sides of the border, potentially leading to massive layoffs.
Semiconductor imports, which approach $40 billion annually, could see equally large disruptions. Key suppliers in Taiwan, South Korea, Malaysia, and the European Union face the prospect of heavy duties that could inflate costs for U.S. tech manufacturers. Higher tariffs threaten to raise semiconductor prices in consumer electronics and industrial equipment, risking a broader slowdown in tech-driven manufacturing.
The pharmaceutical sector also stands on uncertain ground. Current US import data show that packaged medicines and advanced treatments, particularly from the European Union and countries like Switzerland, form a large and rapidly growing segment of American medicine supplies. The administration’s proposal to slap a 25% charge on these imports could cascade into higher prescription costs for Americans, as well as retaliatory steps against US-based pharma operations abroad.
Although Trump has described the measures as “for purposes of fairness,” economists argue that the ad hoc manner of imposing and adjusting tariffs raises the risk of trade wars with close allies. Canada, Mexico, and the European Union have already hinted at retaliation if the tariffs become reality.
Information for this story was found via the sources and companies mentioned. The author has no securities or affiliations related to the organizations discussed. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.
One Response
just a bully backed by Putin and Musk….show me your friends …and it shows who you really are. As for the Ukraine…Trump lies. The world witnessed the first attack by the RUSSIANS…The US needs to be careful or become the 2nd generation .. Nazi Germany…